Lam K Y, Law S Y, So M K, Fok M, Ma L T, Wong J
Department of Pathology, University of Hong Kong, Hong Kong.
Cancer. 1996 Jan 1;77(1):7-13. doi: 10.1002/(SICI)1097-0142(19960101)77:1<7::AID-CNCR3>3.0.CO;2-N.
Proliferative markers are related to tumor behavior. The commonly used markers are proliferating cell nuclear antigen (PCNA) and Ki-67. The aim of this study is to evaluate the usefulness of MIB-1 (for Ki-67) and PC10 (for PCNA) in the assessment of the clinicopathologic features and prognosis in patients with esophageal squamous cell carcinoma.
One hundred patients (88 males, 12 females; mean age, 63 years [range, 39 to 83 years]) with surgically resected esophageal squamous cell carcinoma (32 well differentiated, 51 moderately differentiated, and 17 poorly differentiated) were studied. The clinicopathologic features and survival data of these patients were noted. Representative tissue was collected from each tumor and immunohistochemical preparations for MIB-1 and PC10 were made.
The percentages of cells that tested positive for PC10 and MIB-1 were much higher in tumor cells than in nonneoplastic cells. The pattern of expression of both markers varied with the differentiation of the tumor. The results observed with MIB-1 staining were better than those with PC10; because MIB-1 had less background staining, as well as stronger and more uniform positive signals compared with PC10. Thus, further investigation was performed on MIB-1-stained sections. The tumor cell MIB-1 scores ranged from 169 to 964 positive cells per 1000 cells (mean 598 +/- 211; median, 636). Although it was significantly associated with the differentiation of the tumor (P = 0.0001), the score had no significant relationship to the tumor size, location, or stage, or to the patients' age and sex. The prognosis depended on the size and stage of the lesion. In Stage III lesions (n = 83), patients with MIB-1 scores below 300 had longer actual survival rates than those with a score of 300 or above. However, the survival rates of patients in the latter group were better if the greatest dimension of the tumor diameter was 7.5 cm or less.
Proliferative activity in esophageal squamous cell carcinoma, as defined by the MIB-1 immunohistochemical method, is significantly related to tumor differentiation. It is also potentially valuable as a prognostic marker in addition to its use in tumor staging and size.
增殖标志物与肿瘤行为相关。常用的标志物是增殖细胞核抗原（PCNA）和Ki-67。本研究的目的是评估MIB-1（用于检测Ki-67）和PC10（用于检测PCNA）在评估食管鳞状细胞癌患者临床病理特征及预后中的作用。
对100例经手术切除的食管鳞状细胞癌患者（88例男性，12例女性；平均年龄63岁[范围39至83岁]）进行研究，其中高分化32例，中分化51例，低分化17例。记录这些患者的临床病理特征及生存数据。从每个肿瘤中采集代表性组织，制作MIB-1和PC10的免疫组织化学标本。
肿瘤细胞中PC10和MIB-1检测呈阳性的细胞百分比远高于非肿瘤细胞。两种标志物的表达模式随肿瘤分化程度而异。MIB-1染色的结果优于PC10；因为与PC10相比，MIB-1背景染色较少，阳性信号更强且更均匀。因此，对MIB-1染色切片进行了进一步研究。肿瘤细胞MIB-1评分范围为每1000个细胞中有169至964个阳性细胞（平均598±211；中位数636）。虽然它与肿瘤分化显著相关（P = 0.0001），但该评分与肿瘤大小、位置、分期或患者年龄和性别均无显著关系。预后取决于病变的大小和分期。在III期病变（n = 83）中，MIB-1评分低于300的患者实际生存率高于评分300及以上的患者。然而，如果肿瘤直径最大尺寸为7.5 cm或更小，后一组患者的生存率更好。
用MIB-1免疫组织化学方法定义的食管鳞状细胞癌增殖活性与肿瘤分化显著相关。除用于肿瘤分期和大小评估外，它作为预后标志物也具有潜在价值。
